Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Jones Trading analyst Debanjana Chatterjee initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Buy rating and a...
First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met pri...
Stifel analyst Dae Gon Ha maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target from $80 to $64.
JP Morgan analyst Brian Cheng maintains Intellia Therapeutics (NASDAQ:NTLA) with a Overweight and lowers the price target fr...
RBC Capital analyst Luca Issi maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and lowers the price target fr...
